Impairment of the blood–brain barrier (BBB) integrity is implicated in the numerous
neurological disorders associated with neuroinflammation, neurodegeneration and aging. It …

Over the past years, several lines of evidence support a therapeutic potential of Cannabis
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …

For centuries, hashish and marihuana, both derived from the Indian hemp Cannabis sativa
L., have been used for their medicinal, as well as, their psychotropic effects. These effects …

Glioma is the most common primary malignant brain tumor with poor survival and limited
therapeutic options. The non-psychoactive phytocannabinoid cannabidiol (CBD) has been …

Introduction: Cannabidiol (CBD) as Epidiolex®(GW Pharmaceuticals) was recently
approved by the US Food and Drug Administration (FDA) to treat rare forms of epilepsy in …

Some cannabinoids activate the different isoforms of PPARs (α, β and γ), as shown through
the use of reporter gene assays, binding studies, selective antagonists and knockout …

Cannabidiol (CBD) is a major phytocannabinoid present in Cannabis sativa (Linneo, 1753).
This naturally occurring secondary metabolite does not induce intoxication or exhibit the …

Structural alterations and breakdown of the blood brain barrier (BBB) is often a primary or
secondary consequence of disease, resulting in brain oedema and the transport of …

Cannabidiol (CBD) is the primary non-psychoactive chemical from Cannabis Sativa, a plant
used for centuries for both recreational and medicinal purposes. CBD lacks the psychotropic …

Movement disorders such as Parkinson's disease and dyskinesia are highly debilitating
conditions linked to oxidative stress and neurodegeneration. When available, the …